FDA Launches Landmark Clinical Trial to Assess Kratom's Addiction Potential
核心洞察
Baylor College of Medicine researchers are initiating a $5.5 million FDA-funded clinical trial to evaluate kratom (搜索)'s abuse potential compared to oxycodone, with results expected in three years.
The study will enroll 60 participants to test varying doses of kratom (搜索) against oxycodone and placebo, aiming to inform DEA's regulatory decisions about the widely available herbal supplement.
Recent preliminary FDA research has shown kratom (搜索) leaf capsules to be safe at high doses, marking increased federal interest in understanding this substance used by 2 million Americans annually.
Baylor College of Medicine researchers are preparing to launch a groundbreaking clinical trial this summer to assess the addiction risk of kratom (搜索), a widely available herbal supplement used by millions of Americans. The $5.5 million study, funded by the U.S. Food and Drug Administration, will compare kratom's potential for abuse against the known addictive opioid oxycodone.
Understanding Kratom's Risk Profile
Kratom (搜索), derived from the leaves of a Southeast Asian tree, has gained significant popularity in the United States, with approximately 2 million Americans using it annually for pain relief, managing opioid cravings, and addressing mental health symptoms. The substance is readily available in various forms, including gummies, pills, and beverages, sold through vape shops and online retailers.
"Scientific understanding of its risks and benefits remains limited," notes Dr. Christopher Verrico, lead investigator and associate professor at Baylor College of Medicine. This knowledge gap exists despite kratom (搜索)'s widespread availability and reported cases of overdose deaths and addiction at higher doses.
Clinical Trial Design and Objectives
The study will involve at least 60 participants, randomly assigned to six different groups. Researchers will administer either a placebo, oxycodone, or one of three kratom (搜索) doses ranging from 8 to 16 grams. Participants will rotate through different groups throughout the trial period.
Dr. Ynhi Thomas, co-investigator and assistant professor at Baylor College of Medicine, explains the study's significance: "This research will inform whether we view it as a potentially therapeutic substance or something more like oxycodone that needs to be more regulated."
Regulatory Implications
The trial's outcomes could significantly influence kratom (搜索)'s regulatory status. In 2016, the Drug Enforcement Administration attempted to classify kratom as a Schedule I drug alongside heroin but withdrew the proposal following public opposition. Currently, kratom regulations primarily exist at the state level.
"If it has high abuse potential, the DEA is more likely to place it as a Schedule I or Schedule II drug," Dr. Verrico explains. "If not, they may continue to leave it unscheduled."
Broader Research Initiative
This clinical trial is part of a larger FDA effort to understand kratom (搜索)'s effects. The agency recently completed its first human study, which showed promising safety results for kratom leaf capsules, even at high doses. The upcoming abuse potential study will build upon these findings.
The research team will measure abuse potential by having participants rate their experiences on a sliding scale, evaluating factors such as the intensity of the high, overall sensation, and most crucially, their enjoyment of the drug's effects.
Future Impact
"This research is critical for informing regulatory decisions, guiding public health policies and laying the groundwork for future studies on kratom (搜索)'s therapeutic potential for substance use disorders (搜索) and other conditions," Dr. Verrico emphasizes. While initial findings won't be available for three years, the study represents a significant step toward understanding this widely used but poorly studied substance.